Testosterone and Erythropoiesis
Polycythemia / Erythrocytosis, The Primary Physiological Risk of TRT
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- N/A (physiological mechanism)
Reference only. Not medical advice.
What can go wrong
Elevated hematocrit increases blood viscosity and theoretical thrombotic risk (stroke, venous thromboembolism), though the absolute clinical event rate attributable to TRT-induced erythrocytosis is debated. Hematocrit above 54% conventionally triggers intervention. TRAVERSE recorded numerically more pulmonary embolism in the testosterone arm, keeping thrombotic vigilance relevant.
This is something to take to a clinician. The Atlas can tell you what is known about testosterone and erythropoiesis in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Testosterone is a potent stimulator of red blood cell production. It suppresses hepcidin (increasing iron availability), stimulates erythropoietin, and acts directly on bone marrow progenitors. The result is a rise in hematocrit and hemoglobin, therapeutic in anemia, but a defined hazard in TRT, where testosterone-induced erythrocytosis (often loosely called polycythemia) is the most common and most reliably preventable adverse effect. Hematocrit above ~54% raises blood viscosity and is the conventional threshold for dose reduction, phlebotomy, or cessation.
The number that should be checked more than any other on TRT, and often isn't.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Testosterone increases erythropoiesis by suppressing hepcidin (freeing iron for hemoglobin synthesis), stimulating erythropoietin production, and directly promoting erythroid progenitor proliferation in marrow. Supraphysiological peaks, characteristic of high-dose or infrequent injectable regimens, drive the largest rises, which is why injectable testosterone produces erythrocytosis more often than transdermal gel or nasal formulations.
Why this risk tracks the delivery method
Erythrocytosis is dose- and peak-dependent. Weekly or biweekly intramuscular injections create high serum peaks that drive hematocrit up far more than steady transdermal absorption. The clinical implication is that the same man can have a manageable hematocrit on gel and a dangerous one on the same weekly testosterone dose injected, which is why the monitoring interval (baseline, 3-6 months, then annually) and the route both matter. When monitoring is sparse, as documented in some telehealth settings, rising hematocrit can go undetected until viscosity-related symptoms appear.
Safety in detail
Testosterone-induced erythrocytosis requires baseline and ongoing hematocrit monitoring by a qualified physician. Unmonitored testosterone therapy carries documented risk of dangerously elevated hematocrit and thrombotic complications.
Replacement is not the same as a cycle
Erythrocytosis scales with dose and peak level. Physiological replacement produces modest, monitorable rises; supraphysiological/anabolic dosing produces marked hematocrit elevation and the greatest viscosity and thrombotic risk.
What it does to fertility
Not a direct fertility mechanism, but part of the same exogenous-testosterone exposure that suppresses spermatogenesis; relevant when weighing route and dose.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Baseline hematocrit/hemoglobin before initiation
- Recheck at 3-6 months, then annually
- Action (dose reduction, route change, therapeutic phlebotomy) at hematocrit > 54%
- Reassessment of sleep apnea and smoking as compounding factors
What people get wrong
Often saidHigher red blood cells from testosterone means more energy and endurance
ActuallyBeyond the physiological range, rising hematocrit thickens the blood and raises clotting risk, it is a monitored hazard, not a performance benefit.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Action threshold
- Hematocrit > 54%
- Highest-risk route
- Injectable (peak-driven)
- Lower-risk routes
- Transdermal, nasal
- Mechanism
- Hepcidin suppression + EPO + marrow
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Testosterone and Erythropoiesis. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Endocrine Society Guideline (Bhasin et al.)2018
Designates hematocrit monitoring as a core TRT safety requirement; 54% action threshold
TRAVERSE (Lincoff et al.)2023
Numerically higher pulmonary embolism in testosterone arm